Compare Open Text Corporation (OTEX) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Open Text Corporation vs BIO-TECHNE Corp — how do they compare? Open Text Corporation trades at $22.6 (market cap $5.64B), while BIO-TECHNE Corp trades at $72.39 (market cap $11.34B). The key difference: BIO-TECHNE Corp is far larger — about 2× Open Text Corporation's market cap, and Open Text Corporation pays the higher dividend (4.8%). Which is the better fit depends on your goals.
| OTEX | TECH | |
|---|---|---|
Market Cap | $5.64B | $11.34B |
Sector | Technology | Health |
52-Week High | $39.69 | $72.48 |
52-Week Low | $20.01 | $43.31 |
Enterprise Value | $10.66B | $11.36B |
Dividend Yield | 4.8% | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Open Text Corp (OTEX) trades at $23.36, down 2.46% on the day, with a bearish technical signal but attractive valuation multiples (P/E 9.05, P/S 1.11). Recent earnings beats (Q4 2025, Q1 2026, Q2 2026) and a 4.7% dividend yield highlight fundamental strength. The company announced a $105 million investment in European AI and cloud expansion (PRNewsWire, 2026-06-12), signaling growth initiatives amid mixed institutional positioning.
Outlook: Undervalued with strong cash flow and earnings momentum, but near-term technical pressure and high debt ($6.34B) pose risks. Analyst consensus target of $29.33 suggests 25% upside, supported by cloud revenue growth. Key risks include execution on AI investments and competitive software market dynamics.
Bio-Techne (TECH) trades at $72.31, down 0.17% on the day, with a neutral technical signal and mixed earnings history. The stock is near the consensus price target of $71.86, with a pending acquisition by Merck KGaA at $73.00 per share. Recent Q4 2026 revenue beat estimates, but net income margin compression from 25.09% in 2023 to 14.96% in 2026 highlights profitability challenges. Operating cash flow remains stable around $290M, supporting dividend payments.
The outlook is balanced, with upside capped by the acquisition offer but supported by solid cash flow and analyst hold ratings. Risks include shareholder litigation and integration uncertainties post-acquisition. Earnings growth in diagnostics and spatial biology segments is a key catalyst, though high P/E of 62.33 suggests elevated expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Open Text Corporation
Open Text Corporation is a global leader in Enterprise Information Management (EIM) software and solutions. The company provides a comprehensive platform that helps organizations manage, secure, and leverage their unstructured digital content, including documents, emails, and media files. OTEX's offerings span content management, business process management, customer experience management, and security, serving large enterprises across various industries worldwide.
Read more on OTEX →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
